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Abstract: Plasma fatty acids (FAs) and oxidant status contribute to the etiology of sarcopenia in
the elderly concurring to age-related muscle loss and elderly frailty through several mechanisms
including changes in FA composition within the sarcolemma, promotion of chronic low-grade
inflammation, and insulin resistance. The aim of this study was to determine the FA profile and
pro-antioxidant status in sarcopenic frail elderly patients enrolled in a nutritional and physical
activity program and to evaluate their correlation with clinical markers. Moreover, the possible
changes, produced after a short-term clinical protocol, were evaluated. Plasma and erythrocyte FA
composition and pro-antioxidant status were analyzed in sarcopenic elderly subjects recruited for the
randomized clinical study and treated with a placebo or dietary supplement, a personalized diet, and
standardized physical activity. Subjects were tested before and after 30 days of treatment. Pearson
correlations between biochemical parameters and patients’ characteristics at recruitment indicate
interesting features of sarcopenic status such as negative correlation among the plasma FA profile,
age, and physical characteristics. Physical activity and dietetic program alone for 30 days induced
a decrease of saturated FA concentration with a significant increase of dihomo-gamma-linolenic
acid. Supplementation plus physical activity induced a significant decrease of linoleic acid, omega-6
polyunsaturated FAs, and an increase of stearic and oleic acid concentration. Moreover, glutathione
reductase activity, which is an indicator of antioxidant status, significantly increased in erythrocytes.
Changes over time between groups indicate significant differences for saturated FAs, which suggest
that the amino acid supplementation restores FA levels that are consumed during physical activity.
A relationship between FA and clinical/metabolic status revealed unique correlations and a specific
metabolic and lipidomic fingerprint in sarcopenic elderly. The results indicate the positive beneficial
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role of supplementation and physical activity on plasma FA status and the antioxidant system as a
co-adjuvant approach in sarcopenic, frail, elderly patients.
Keywords: fatty acid; antioxidants; elderly; sarcopenia; frailty; exercise; supplement
1. Introduction
Sarcopenia is a multifactorial syndrome emerging from changes in muscle morphology, oxidative
stress, inflammation, physical activity, and diet [1,2]. Oxidative stress moderates aging and exacerbates
age-associated diseases [3–5]. It is an etiological factor in the development of sarcopenia [6]. Elevated
metabolic activity of skeletal muscle increases the production of reactive oxygen species (ROS), which
increases oxidative stress [7]. Antioxidant enzymes, therefore, are important for skeletal muscle
adaptation to increased physical activity with contrasting experimental findings revealing both a
compensatory induction of antioxidant activity [8] as well as antioxidant systems’ dysfunction [9]
during aging. Superoxide dismutase (SOD) is responsible for the dismutation of the superoxide
anion, O2., and the elimination of cellular oxidative stress. The absence of the cytosolic SOD1 isoform
significantly decreases the lifespan [10]. Recent findings reveal that high levels of oxidative stress
accelerated sarcopenia due to O2. induced neuromuscular degeneration and mitochondrial dysfunction
in SOD1-deficient mice [4,11,12]. Pansarasa et al. [8] proposed an association between ROS activity
and age-related changes in human skeletal muscle, while Mecocci et al. [13] demonstrated age-related
oxidative damage and significant loss of muscle mass. Increased levels of hydrogen peroxide (H2O2)
have been found in aging skeletal muscle. Capel et al. [14] demonstrated an increase in mitochondrial
H2O2 release in the tibialis anterior (TA) muscles of 24-month old male Wister rats with sarcopenia
when compared to 4.5-month controls. Capel et al. [15] confirmed increased mitochondrial H2O2
release in the vastus lateralis muscle of elderly subjects. Animal models have been critical for our
understanding of human sarcopenia [16]. Mitochondria obtained from aged rodent muscle fibers
displayed several functional abnormalities by explaining the increased proteolysis associated with
ROS overproduction and vulnerability to apoptosis exhibited by the sarcopenic muscle.
Noteworthy, these deleterious changes appear to be related to modifications of the fatty acid (FA)
profile of mitochondrial phospholipids [17]. Aging was found to be correlated with a decrease of
stearic acid, which leads to a reduction in the percentage of saturated FAs. On the other hand, it raised
the proportion of oleic acid and total monounsaturated FAs. The total content of polyunsaturated FAs
was not modified, but the nature of these FAs was changed.
Dietary fats are a major source of energy for resting and working muscle and can exert effects on
age-related muscle loss through several mechanisms. These include changes in FA composition within
the sarcolemma (muscle cell membrane), promotion of chronic low-grade inflammation, and insulin
resistance [18–20].
Lipina and Hundal [21] in their review discussed the role of FAs and their derived lipid
intermediates in the regulation of skeletal muscle mass and function, which underlies the importance
of lipidomic evaluations related to the possible lipid influence on muscle metabolism, structure, and
strength. Despite the heightened awareness of the role of oxidative status in the development of
sarcopenia, as well as fat function in muscle energy production during exercise and the potential for
fats to influence mechanisms associated with muscle loss, there is a paucity of data integrating these
factors in human sarcopenia.
The aim of this study was to determine the FA profile and pro-antioxidant status in sarcopenic,
frail, elderly patients enrolled in a nutritional and physical activity program in order to evaluate
their correlation with clinical markers. Moreover, this study has evaluated the possible changes
produced after a short-term clinical supplementation protocol designed to counteract elderly sarcopenia,
promoting muscle accretion compared to placebo.
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Relationship between FA and clinical/metabolic status, determined by physical and
hemato-chemical parameters, body composition assessed with bioimpedance, and psychological
assessment, revealed interesting correlations and a specific metabolic and lipidomic fingerprint in
sarcopenic elderly. The results indicate the positive beneficial role of supplementation and physical
activity on the plasma FA status and antioxidant system as a co-adjuvant approach in sarcopenic, frail,
elderly patients.
2. Materials and Methods
2.1. Participants
The Ethics Committee of the Department of Internal Medicine and Medical Therapy and the
Institutional Review Board at the University of Pavia approved this study. All participants were
informed about the study, gave their written consent, and were guaranteed confidentiality and
anonymity (ClinicalTrials.gov Identifier: NCT02402608).
Subjects were elderly men and women admitted to the geriatric physical medicine and
rehabilitation division at the Istituto Santa Margherita, Azienda di Servizi alla Persona di Pavia
(Pavia, Italy).
All participants underwent a medical examination before enrolment in the study. Eligible patients
were 65 years or older with appendicular skeletal fat-free mass (FFM) divided by height squared two
standard deviations (SD) below the mean of young adults [22] or relative muscle mass <7.26 kg/m2
for men and <5.5 kg/m2 for women. Patients were not affected by acute illness, severe liver, heart
or kidney dysfunction, and had a stable body weight over the preceding six months. Subjects with
altered glycometabolic control, dysthyroidism, other endocrinopathies, and cancers, as well as patients
treated with steroids and heparin, or with total walking incapacity were excluded. At enrollment, the
functional status was assessed using instrumental activities of daily living (IADLs), and cognitive
status was assessed with the Mini-Mental State Examination (MMSE) [23].
The patients’ fasting blood biochemical indices of nutritional and health status (total and low
density lipoprotein (LDL) serum cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol,
total proteins and albumin, total bilirubin, iron, glucose, uric acid, creatinine, and liver enzymes, such
as transaminase alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl
transferase (gamma-GT), C-reactive protein (CRP), erythrocyte, white blood cell and platelet counts,
hemoglobin concentration, mean cell volumes, mean cell hemoglobin concentrations, and insulin-like
growth factor I (IGF-I) were evaluated at the time of recruitment.
The plasma FA profile and malondialdehyde (MDA), erythrocyte antioxidant enzymes and FA
profile, were assessed at the start of the study and after 30 days of hospitalization during the 12-week
controlled phase of the trial. The anthropometric, biochemical, nutritional, and dietary pattern methods
used were previously described in detail [24].
2.2. Dietetic Program
All subjects were provided with three meals a day, which were prepared fresh each day in the
hospital kitchen under the supervision of a dietitian. Diets were planned on a four-week rotating
menu based on recommended caloric and macronutrient and micronutrient content [25]. A calibrated
dietetic spring scale was used to weigh the items of food served to and returned by the subjects for
three consecutive days at the beginning and end of the study. Nurses who served food to the subjects
between meals recorded the quantity of food consumed in household measurements. The energy value
and the macronutrient content of the consumed food was calculated by using a computer program
(DR3 v3.1.0, Sintesi Informatica, Milan, Italy).
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2.3. Physical Activity
All participants underwent a comprehensive, progressive physical fitness and muscle mass
enhancement training program of moderate intensity [26]. The exercise intervention was supervised
by trained personnel and included 20 minutes of exercise per day, five times per week, for 12 weeks.
Each exercise session consisted of a 5-minute warm-up, 5 minutes of strengthening exercise, 5 minutes
of balance and gait training, and 5 minutes of cool-down. The strengthening exercises were done in a
progressive sequence from seated to standing positions [27]. For each type of exercise, participants
were instructed to repeat the movements up to eight times. Intensity was maintained at approximately
12 to 14 on the Borg Rate of Perceived Exertion scale [28]. Each subject’s ability to increase intensity
was assessed.
Compliance to the exercise program was set a priori at a minimum of 70%. The exercise sessions
were done outdoors, weather permitting, and were performed as follows:
- Chair exercise: repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were
done while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises
were done while standing upright behind the chair, holding the back of the chair for stability.
- Ankle-weight exercise: to strengthen the legs, a fixed weight was placed on the ankle while
participants did strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were prepared
and used in accordance with each participant’s strength as the resistance progressively increased.
The exercises using these ankle weights included seated knee flexion and extension as well as
standing knee flexion and extensions.
- Exercises with a resistance band: resistance bands were used to strengthen the upper and lower
body. Lower-body exercises included leg extension and hip flexion. Upper-body exercises
included double-arm pull downs and bicep curls.
- Balance and gait training: exercises included standing on one leg, multidirectional weight shifts,
tandem stand, and tandem walk. Participants practiced proper gait mechanics focused on
maintaining stability during walking and increasing stride length, toe elevation of the forward
limb, heel elevation of the rear limb, frequency of stepping, and a heel-floor angle. Exercises
included raising the toes (dorsiflexion) during the forward swing of the leg, kicking off the floor
with the ball of the foot, walking with directional changes, and gait pattern variations.
2.4. Dietary Supplementation
Participants were assigned to treatment or placebo groups, according to a coded block
randomization table prepared by an independent statistician. The intervention treatment was a
liquid supplement (32 g) containing essential amino acids (EAA), whey protein, and a vitamin
D mixture (SAI nutrition Gardanne, France). The chemical composition and its effectiveness in
counteracting sarcopenia were previously published (Supplemental Table S1). The control group was
given a placebo consisting of an isocaloric amount of maltodextrin with the same flavor and appearance
as the intervention product. The dietary supplement or placebo was administered orally with meals
once a day at midday for 12 weeks.
Investigators were blinded to the randomization table, the code assignments, and the procedure.
Enrolled patients were assigned a progressive number. The supplements were distributed to the
patients daily by a research dietitian, who was blinded to the randomization schedule. All supplements
were in powder form and packed in numerically coded bottles. Instructions on each bottle included
the amount of water that needed to be added. Study participants mixed the water and content of
the bottle, so the product was ready for consumption. Participants were instructed to consume their
normal amounts of food together with the dietary supplement.
Safety was assessed by the absence of serious side effects from the supplement (e.g., gastrointestinal
symptoms such as nausea and diarrhea). Each subject was interviewed daily by a dietician about any
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unwanted side effects. Compliance with consumption of the supplement and placebo was 100%. No
participant refused to take the supplement, and no side effects were reported.
2.5. Blood Sampling
Fasting blood samples were collected, for routine biochemical and hemato-chemical analyses. For
biochemical assays, each blood sample (3 mL) was drawn and collected in heparinized glass tubes.
The heparin tubes after gentle agitation were centrifuged at 3000 rpm at 4 ◦C for 10 minutes. After
centrifugation, aliquots of 300 µL of plasma were immediately separated and frozen in dry ice. Then
the samples were stored at −80 ◦C until use. Erythrocytes or red blood cells (RBC) were washed in
phosphate-buffered saline and aliquots of 150 µL were stored at −80 ◦C in isotonic buffer and butylated
hydroxytoluene (0.2%) as an antioxidant until subsequent use for membrane purification.
2.6. Lipid Analysis
RBC membranes (Ghost) were prepared by lysis with hypotonic buffer (phosphate 5 mM, pH
8, EDTA 0.5 mM), precipitated by centrifugation and washed several times to eliminate hemoglobin
residues. Ghosts were used to assess cell membrane fatty acids. To this aim, ghost lipids were
extracted according to Folch [29] with three different chloroform/methanol mixtures, as previously
described [30,31].
FA composition of plasma and RBC Ghost organic extract was determined by gas chromatography.
FA methyl esters, obtained after derivatization with sodium methoxide in methanol 3.33% w/v, were
injected into a gas chromatograph (Agilent Technologies 6850 Series II, Santa Clara, USA) equipped
with a flame ionization detector and an Alltech capillary column AT-Silar (30 m × 0.32 mm i.e., film
thickness of 0.25 µm) under the following experimental conditions: gas carrier: helium, temperature:
injector 250 ◦C, detector 275 ◦C, oven 50 ◦C for 2 min, and rate of 10 ◦C min−1 until 200 ◦C for 20 min.
A standard mixture containing FA methyl esters was injected for calibration. All samples were blinded
for the treatment group (supplemented or control).
2.7. Plasma Malondialdehyde (MDA) Analysis and Erythrocyte Antioxidant Enzymes
Lipid peroxidation product levels, as MDA, were measured in plasma by high-performance liquid
chromatography (Jasco, Tokyo, Japan) equipped with an auto-sampler and a UV detector as previously
reported [32].
Erythrocyte lysates were obtained from washed cells after two cycles of freezing and unfreezing
followed by centrifugation to discard cell membranes. The hemolyzed fraction was tested for catalase
(CAT), glutathione peroxidase (GPX), glutathione reductase (GR), and superoxide dismutase (SOD)
enzyme activities, as previously described [33]. Hemoglobin concentration was determined on RBC
lysate and used to normalize enzyme determinations [34] and Ghost FA content.
To determine glutathione content (GSH+GSSG), fresh erythrocytes were treated with 10%
metaphosphoric acid. The homogenate was centrifuged at 5000 g for 10 minutes at 4 ◦C, and
the supernatant was assayed according to the method described by Griffith [35], with some slight
modifications. The sulfhydryl group of GSH, also generated from glutathione GSSG, by adding GR,
reacts with 5,5-dithio-bis-2-nitrobenzoic acid and produces a yellow colored 5-thio-2-nitrobenzoic acid
(TNB). The rate of TNB production is directly proportional to this reaction, which, in turn, is directly
proportional to the concentration of GSH in the sample. The measurement of the absorbance of TNB at
412 nm provides an accurate estimation of the GSH level present in the sample.
2.8. Statistical Analysis
The clinical study consisted of a 12-week, randomized, double-blind, placebo-controlled
supplementation trial. Nevertheless, results reported in this paper were obtained after 30 days
of treatment.
Nutrients 2019, 11, 2569 6 of 18
The correlation of clinical and metabolic characteristics with lipidomic and antioxidant status of
all participants at recruitment was assessed with linear regression models. The Pearson R correlation
coefficients and 95% confidence intervals (CIs) were computed.
Within and between-groups changes of fatty acids were assessed by means of regression models for
repeated measures and calculation of Huber-White robust standard errors to account for intra-patient
correlation of measures. Differences within/between groups and 95% confidence intervals were
computed. These analyses should be regarded as exploratory. Model assumptions were assessed
graphically. Stata 14 (StataCorp, College Station, TX, USA) was used for computation.
The calculation of the sample size was based on a previous study [24].
3. Results
One hundred sixty-two elders were enrolled in the clinical trial and 130 participants were
randomized. Thirty-two individuals were excluded because they either declined to participate (n = 11)
or had abnormal laboratory values (n = 21).
The baseline characteristics, body composition, and psychological scores for the supplemented (S)
and placebo-treated (P) groups were similar during the study admission (Table 1). Dietary intakes
during hospitalization were similar for both groups (Supplemental Table S2).
Table 1. Baseline characteristics of the participants 1.
Supplement Group
(69 Subjects)
Placebo Group
(61 Subjects)
Characteristics
Age (y) 80.77 ± 6.29 80.21 ± 8.54
Male N (%) 29 (42%) 24 (39%)
Smokers N (%) 3 (4%) 5 (8%)
Level of schooling (years) 7 (3–11) 5 (2–9)
Body composition
Fat free mass (kg) 39.90 ± 8.13 38.71 ± 8.37
Fat mass (kg) 17.81 ± 6.78 19.21 ± 9.18
Gynoid (%) 35.79 ± 9.67 37.67 ± 10.60
Android (%) 34.21 ± 10.76 34.26 ± 12.85
RSMM (kg/m2) 6.60 ± 1.19 6.36 ± 1.32
MNA (score) 17.84 ± 3.07 17.84 ± 3.57
Weight (kg) 59.47 ± 11.16 59.39 ± 13.51
BMI (kg/m2) 23.85 ± 3.63 23.93 ± 4.60
Wrist circumference (cm) 16.29 ± 1.75 16.08 ± 1.42
Arm circumference (cm) 25.22 ± 3.36 25.02 ± 3.80
Calf circumference (cm) 30.43 ± 3.13 29.95 ± 4.55
Waist circumference (cm) 88.95 ± 9.74 89.01 ± 10.15
Handgrip (kg) 16.63 ± 4.99 19.62 ± 6.01
Psychological scores
MMSE (score) 21.78 ± 3.70 20.5 ± 4.93
ADL (score) 3.97 ± 1.19 4.03 ± 1.08
SF-36 MCS (score) 46.65 ± 10.7 44.0 ± 9.7
SF-36 PCS (score) 34.1 ± 10.2 37.1 ± 11.0
1 Data are shown as mean± SD, median (25th–75th) unless otherwise specified [24]. RSMM = Relative Skeletal Muscle
Mass. MNA = Mini Nutritional Assessment. BMI = Body Mass Index. MMSE = Mini Mental State Examination.
ADL = Activity Daily Living. SF-36 MSC = SF-36 mental components. SF-36 PCS = SF-36 physical components.
We previously reported the effects of 12 weeks of supplementation vs. placebo with physical
training on body composition [24]. Changes in free fat mass (FFM) were significantly different between
the two groups with a mean difference of 1.7 kg (95% CI 0.9–2.5, p < 0.001) and greater increases in the
S group (1.4 kg, p < 0.001) and no significant change in the P group (0.3 kg).
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In this paper, we try to depict the metabolic status of the frail sarcopenic elderly by analyzing
different biochemical, metabolic and clinical parameters to find possible correlations that describe
these patients.
In Table 2, the average baseline biochemical characteristics for all the elderly participants are
reported. Searching for metabolic and biochemical markers of frailty in sarcopenic elderly patients, we
analyzed the correlations of the different measured parameters at study enrolment.
Figure 1 depicts a heat map where we report the Pearson coefficients for statistically significant
correlations (p < 0.05) between elderly features such as body composition, psychological scores,
osteoporosis incidence, and bioimpedance indexes at the start of the study.
Table 2. Baseline biochemical parameters of the participants 1.
Hematology Supplemented Group Placebo Group
Proteins (g/dL) 6.67 ± 0.55 6.56 ± 0.61
Albumin (g/dL) 3.76 ± 0.54 3.6 ± 0.55
Albumin (%) 55.92 ± 5.82 54.83 ± 6.00
Creatinine (mg/dL) 0.95 ± 0.7 0.91 ± 0.38
Azotaemia (mg/dL) 45.00 ± 35.41 46.92 ± 22.42
Uric Acid (mg/dL) 5.00 ± 2.20 5.15 ± 1.89
CRP (mg/L) 0.30 (0.14–1.23) 0.33 (0.16–1.03)
IGF-I (ng/mL) 80.6 ± 33.8 82.7 ± 38.8
White Blood Cell (109/L) 6.96 ± 2.06 7.39 ± 3.08
Red Blood Cell (1012/L) 4.27 ± 0.48 4.24 ± 0.84
Hemoglobin (g/dL) 12.60 ± 1.47 12.19 ± 1.77
Hematocrit % 38.20 ± 4.25 36.91 ± 6.31
Platelet count (109/L) 245.94 ± 85.38 240.14 ± 147.75
Lymphocyte count (109/L) 1.80 ± 0.59 2.38 ± 3.88
Lymphocytes % 27.18 ± 8.51 25.92 ± 10.88
Iron (µg/dL) 72.46 ± 30.65 65.60 ± 30.79
Transferrin (g/L) 2.19 ± 0.50 2.15 ± 0.76
Glycaemia mmol/L 5.96 ± 2.12 5.51 ± 1.78
Triglyceride mmol/L 3.01 ± 1.09 3.32 ± 1.92
Total Cholesterol mmol/L 5.05 ± 1.21 4.9 ± 1.42
High-Density Lipoprotein mmol/L 1.35 ± 0.41 1.17 ± 0.38
Low-Density Lipoprotein mmol/L 3.14 ± 1.02 2.71 ± 1.48
Sodium (mEq/L) 138.88 ± 2.74 139.43 ± 2.92
Potassium (mEq/L) 4.06 ± 0.42 4.25 ± 0.61
Chlorine (mEq/L) 103.71 ± 3.86 104.83 ± 4.24
Calcium (mg/dL) 9.15 ± 0.63 9.02 ± 0.54
Amylase (U/L) 32.53 ± 24.31 28.60 ± 12.40
Total Bilirubin (mg/dL) 0.74 ± 0.47 0.71 ± 0.35
AST (U/L) 19.01 ± 10.54 21.52 ± 19.19
ALT (U/L) 16.35 ± 11.94 20.08 ± 18.22
gGT (U/L) 32.31 ± 38.43 36.70 ± 42.17
1 Data are shown as mean ± SD. Median (25th–75th) unless otherwise specified [24]. CRP = C-Reactive Protein.
IGF-I = insulin like growth factor-I.
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features at recruitment.
Furthermore, Figure 2 reports the correlations between biochemical parameters and patients’
characteristics. A negative correlation was observed between the plasma FA profile and age, and
physical characteristics (underlined in blue). In particular, the saturated and omega-6 polyunsaturated
fatty acids (PUFAs) display the highest correlation.
On the contrary, lipid composition of the ghost RBC showed a significant negative correlation
with psychological scores (highlighted in violet), including palmitic and omega-6 PUFAs. The same
correlations are displayed by RBC GPX activity.
Figure 3 reports significant correlations between the lipid profile and antioxidant potential
measured in blood with the hemato-chemical parameters of the sarcopenic, elderly patients at the start
of the study. It is worthy of note that the collected data demonstrate a positive correlation between
specific plasma FAs and circulating neutral lipids such as LDL cholesterol and triglycerides. It is
important to highlight the positive relationship between vitamin B12 and plasma FAs, which was more
marked for eicosapentaenoic acid (EPA) in the sarcopenic, elderly patients.
RBC lipids, which include palmitic, stearic, and gamma-linolenic acids, positively correlate with
inflammatory markers such as VES and PCR.
Regarding the antioxidant status, MDA levels negatively correlate with circulating lipoproteins
while positively correlating with creatinemia, azotemia, and amylase. Of interest was the association
between uric acid and MDA (p < 0.001) (Figure 4).
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Moreover, we analyzed the short time effects, after 30 days, of the study protocol (dietetic regimen,
exercise, and supplementation) on plasma lipid composition and antioxidant status. As shown in
Table 3, the placebo group, during hospitalization, underwent combined physical activity with a
standard diet program for one month, which s ow a decreas of palmitic acid and ted FAs
(p = 0.007 and .012, respectively) with a significant increase of dihomo-gamma lino e ic acid (DGLA)
(p = 0.014). An increase in plasma MDA concentration and in the EPA proportion were also present,
even if they were not significant (p = 0.084 and 0.076, respectively).
Table 3. Effects of a 30-day clinical trial on plasma fatty acids and oxidative stress markers of physical
activity and amino acid supplementation in elderly sarcopenic subjects (n = 69 in the supplementation
group, n = 61 in the placebo group).
Fatty Acid
lacebo Group Supplemented Group
PRE POST p Value PRE POST p Value
Palmitic acid (C16:0) 30.1 ± 3.52 28.1 ± 3.70 0.007 29.2 ± 3.01 29.3 ± 2.95 0.843
Palmitoleic acid (C16:1) 3.63 ± 1.14 3.83 ± 1.52 0.209 3.63 ± 1.25 3.55 ± 0.99 0.528
Stearic acid (C18:0) 5.75 ± 0.95 5.76 ± 1.02 0.952 5.61 ± 0.69 6.08 ± 0.85 0.001
Oleic acid (C18:1) 24.2 ± 6.44 25.4 ± 3.73 0.265 24.1 ± 3.21 25.0 ± 2.79 0.046
Linoleic acid (C18:2) 22.9 ± 4.19 22.1 ± 3.80 0.190 23.2 ± 3.23 21.6 ± 3.81 0.002
α-linolenic acid (C18:3 n-3) 0.44 ± 0.17 0.48 ± 0.18 0.206 0.53 ± 0.29 0.60 ± 0.52 0.347
γ-linolenic acid (C18:3 n-6) 0.23 ± 0.18 0.30 ± 0.29 0.191 0.25 ± 0.30 0.28 ± 0.25 0.504
Dihomo-γ-linolenic (C20:3 n-6) 1.30 ± 0.34 1.4 ± 0.39 0.014 1.36 ± 0.91 1.44 ± 0.32 0.496
Arach d nic acid (C20:4 n-6) 9.24 ± 2.48 10.31 ± 7.27 0.325 9.64 ± 2.73 9.81 ± 2.67 0.655
Eicosapentaenoic acid (C20:5 n-3) 0.34 ± 0.19 0.43 ± 0.17 0.076 0.42 ± 0.15 0.45 ± 0.18 0.199
Docosapentaenoic acid (C22:5 n-3) 0.42 ± 0.18 0.41 ± 0.10 0.593 0.42 ± 0.12 0.43 ± 0.10 0.694
Docosahexaenoic acid (C22:6 n-3) 1.50 ± 0.42 1.49 ± 0.41 0.927 1.57 ± 0.58 1.51 ± 0.48 0.424
AA/EPA 29.3 ± 12.3 26.3 ± 16.6 0.299 24.9 ± 8.56 24.5 ± 9.77 0.809
Saturated fatty acids 35.8 ± 3.75 33.9 ± 3.94 0.012 34.8 ± 2.99 35.4 ± 3.21 0.229
Monounsaturated fatty acids 27.8 ± 6.47 29.2 ± 4.21 0.168 27.8 ± 3.65 28.5 ± 3.02 0.112
Polyunsaturated fatty acids 36.4 ± 5.4 36.9 ± 6.21 0.604 37.6 ± 4.56 36.1 ± 4.27 0.024
Omega-6 33.6 ± 5.23 34.1 ± 6.21 0.654 34.5 ± 4.35 33.1 ± 4.13 0.028
Omega-3 2.73 ± 0.57 2.81 ± 0.54 0.381 2.93 ± 0.80 3.00 ± 0.83 0.618
Omega-6/Omega-3 ratio 12.9 ± 3.97 12.7 ± 4.32 0.809 12.4 ± 2.84 11.8 ± 3.23 0.155
Plasma Malondialdehyde (µM) 3.78 ± 1.91 4.20 ± 1.98 0.084 3.42 ± 1.68 3.51 ± 1.75 0. 63
Superoxide dismutase (U/g Hb) 4724 ± 2499 4800 ± 2868 0.891 4413 ± 2520 44 5 ± 2269 0.937
Total GSH (nmol/mg Hb) 4.08 ± 1.45 4.33 ± 1.93 0.408 4.35 ± 1.23 4.34 ± 1.61 0.981
Glutathione Reductase (U/g Hb) 3.06 ± 1.16 3.23 ± 1.13 0.352 2.59 ± 0.66 2.85 ± 0.88 0.031
Glutathione Peroxidase (U/g Hb) 28.6 ± 16.2 30.2 ± 16.0 0.553 36.3 ± 13.6 31.2 ± 18.1 0.084
Fatty acids are reported as the percentage of total plasma fatty acids. Malondialdehyde was assayed in plasma,
while antioxidant enzymes and glutathione were assayed in erythrocyte lysates and normalized to hemoglobin
content (Hb). AA/EPA = Arachidonic acid/Eicosapentaenoic acid.
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Supplementation combined with physical activity and a standard diet program induced a
significant decrease of linoleic acid (LA) and omega-6 PUFAs (p = 0.002 and 0.028, respectively) together
with an increase in plasma stearic and oleic acid concentrations (p = 0.001 and 0.046, respectively).
Moreover, the antioxidant marker GR increased (p = 0.031, Table 3).
Table 4 shows changes over time between the groups. Significant differences were present for
palmitic, stearic, and saturated FAs (p = 0.034, 0.011, and 0.008, respectively), which suggests that the
supplement restores saturated FA levels that are consumed during physical activity.
Table 4. Between group differences on plasma fatty acids and oxidative stress markers of the sarcopenic
elderly. The placebo group was under a controlled diet and performs physical activity, while the
supplemented group also takes the dietary supplement (n = 69 in the supplementation group, n = 61 in
the placebo group).
Variables ∆ (95%)Between Groups
p Value
Treatment Effect
Palmitic acid 1.73 (0.13 to 3.33) 0.034
Palmitoleic acid −0.31 (−0.71 to 0.10) 0.137
Stearic acid 0.58 (0.14 to 1.02) 0.011
Oleic acid −0.69 (−2.80 to 1.42) 0.520
Linoleic acid −0.25 (−1.88 to 1.39) 0.765
α-linolenic acid 0.02 (−0.17 to 0.22) 0.799
γ-linolenic acid 0.03 (−0.10 to 0.16) 0.656
Di-homo-γ-linolenic −0.08 (−0.39 to 0.23) 0.622
Arachidonic acid −0.96 (−3.05 to 1.14) 0.366
Eicosapentaenoic acid −0.02 (−0.09 to 0.05) 0.622
Docosapentaenoic acid −0.00 (−0.05 to 0.05) 0.912
Docosahexaenoic acid -0.09 (-0.28 to 0.10) 0.349
AA/EPA 1.19 (−4.89 to 7.27) 0.699
Saturated fatty acids 2.31 (0.61 to 4.01) 0.008
Monounsaturated fatty acids −0.99 (−3.11 to 1.12) 0.354
Polyunsaturated fatty acids −1.47 (−3.87 to 0.93) 0.226
Omega-6 −1.25 (−3.66 to 1.15) 0.303
Omega-3 −0.07 (−0.40 to 0.26) 0.673
Omega-6/Omega-3 0.27 (−1.48 to 2.01) 0.763
Malondialdehyde −0.36 (−0.98 to 0.25) 0.243
Superoxide dismutase 702 (−682 to 2086) 0.316
Glutathione 0.02 (−0.54 to 0.58) 0.951
Glutathione reductase −0.002 (−0.41 to 0.41) 0.993
Glutathione peroxidase −7.71 (−15.92 to 0.49) 0.065
Fatty acids and Malondialdehyde were assayed in plasma, while antioxidant enzymes and glutathione were
assayed in erythrocyte lysates and were normalized to hemoglobin content (Hb). AA/EPA = Arachidonic
acid/Eicosapentaenoic acid.
4. Discussion
While the etiology of sarcopenia is multifactorial, a consensus is emerging that oxidative damage
of skeletal muscle is a modifiable risk factor to consider in the development of this condition [36].
Physical activity, which can attenuate the development of sarcopenia, can also enhance production of
ROS that adversely affects muscle membranes and promotes proteolysis of muscle [37].
The dietary intake of FAs is known to influence the FA composition of stored and structural
lipids in different body compartments, such as erythrocytes and serum lipids [38–41]. Furthermore,
dietary lipids impact the circulating FAs that, in turn, reflect the composition of the skeletal muscle
membranes [18,42].
Alterations in membrane lipid composition play a central role in sarcopenia being able to modulate
mitochondrial function. The FA membrane content may affect aging by protecting membranes against
lipid peroxidation and preventing oxidative stress that influences membrane proteins and functions.
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The manipulation of membrane FA content by diets that differ in lipid composition induces changes
in mitochondrial phospholipid FAs that reflect the PUFA profile of the dietary lipid sources [43].
The increased degree of saturation may protect against ROS in the skeletal muscle mitochondria,
not only in relation to the decrease of lipid peroxides but also influencing mitochondrial respiration
through a protonophoric effect on the inner cristae membrane, and an inhibitory action on the electron
transfer chain.
The findings of the present study in the elderly provide evidence of a correlation among plasma
and the RBC lipid phenotype with clinical, physical, and hematological characteristics. The possibility
to ameliorate the lipid profile with diet, exercise, and supplementation is also presented.
Among the placebo-treated elders, consumption of a standard control-diet combined with regular
exercise, even for a short time, induced a decrease of saturated FAs, especially palmitic acid, while the
increase of MDA likely indicates the presence of oxidative stress induced by exercise.
Senescent muscle is susceptible to oxidative stress during exercise due to the age-related
ultrastructural and biochemical changes that facilitate ROS formation. Furthermore, the reduction
of muscle repair and regeneration capacity with old age could potentially enhance cellular oxidative
damage. While endurance exercise is an effective way to maintain muscle mass during old age, it also
increases free radical generation and, thus, the risk of oxidative damage to skeletal muscle [44].
On the contrary, the use of a dietary supplement, enriched with branched-chain amino acids
(BCAAs), reverts the lipid phenotype of the patients. It appears that the fatty acid anabolism is
stimulated by the supplement causing an increase of stearic acid and oleic acid, while palmitic acid
levels, which decreased in patients in the placebo group, retain the same concentration. This suggests
the possible conversion of BCAAs to lipids, or their utilization as an energy source in muscles during
exercise. This preserves circulating saturated FAs.
Cross-sectional studies have suggested that elevations in plasma BCAAs are linked to markers of
insulin resistance and adipose tissue FA synthesis. However, contrasting results are present in the
literature [45]. For this reason, the correlation of BCAA use and the plasma lipidomic fingerprint is
an important topic for future research because of the widespread use of BCAAs and whey protein
as anabolic supplements. It is important to highlight that the decrease of LA and omega-6 PUFAs
indicates a lower inflammatory state in the elderly subjects. Furthermore, supplemented subjects did
not show an increase in MDA levels, but rather an induction of antioxidant enzymes, which may be
related to the changes in muscle metabolism in the presence of BCAAs.
Fat is a major source of energy for resting and working muscles and may exert effects on
age-related muscle loss through a number of mechanisms, including by influencing the FA composition
of the sarcolemma membrane, increasing chronic low-grade inflammation (circulating cytokines), and
diminishing insulin sensitivity [18,19,46,47].
The study by Sitnick et al. [48] sheds new light on the role of muscle and fat in lifestyle-related
diseases. The researchers showed that chronic consumption of a high saturated fat and cholesterol-rich
diet impairs the ability of murine skeletal muscle to hypertrophy in response to a mechanical load.
Thus, these findings suggest that a high fat diet may not only increase fat mass but may also decrease
muscle mass.
Nevertheless, to date, only two observational studies have correlated the FA profile with skeletal
muscle mass [49,50]. These studies reported dietary fat intake among middle age and active people,
which was estimated by food frequency questionnaires and not by blood FA profiling that reflects
cell membrane composition. It is worth mentioning that these studies reported significant negative
correlation coefficients between saturated fat intake and appendicular lean mass in adults (r = 0.97,
p < 0.001, r = 0.99 in women, and r = 0.98 in men).
Low intensity exercise affects the blood FA profile. In the study of Andersson et al. [51] a group of
sedentary middle-aged Swedish men, during 10 weeks, on a standardized diet with an identical fat
composition, were randomized to remain sedentary or begin with low intensity physical activity. They
demonstrated that exercise decreases skeletal muscle phospholipid FAs, especially palmitic acid, LA,
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and the sum of omega-6 PUFAs. Although a limitation of their study was the lack of a controlled diet,
those results are consistent with the changes in the FA profile of the present study.
Moreover, recent findings indicate that long-term consumption of a high fat diet favors the
accumulation of long-chain PUFAs in male rats, which induce the release of chemokines that may
contribute to muscle mass loss [52].
Regarding the specific changes of the FA profile in our groups, an interesting and new finding
of this study is the increase of oleic acid in association with the significant decrease in LA that was
observed in the pre-supplemented and post-supplemented groups.
A previous animal model study demonstrated that oleic acid might play a favorable, pivotal role
in skeletal muscle regeneration, while LA conversely impairs muscle regeneration [53].
Moreover, oleic acid improves the lipid profile [54], maintains a balance of body weight [55], and
prevents palmitate-induced mitochondrial dysfunction, insulin resistance, and inflammatory signaling
in neuronal cells [56] and skeletal muscle [57].
The increase of oleic acid may also explain the decrease of the CRP that was found in the present
study, due to its anti-inflammatory activity [58] paralleled by the reduction of pro-inflammatory
omega-6 PUFAs. Candow et al. [59] demonstrated that omega-6 PUFAs may augment the loss of
muscle mass, and that the omega-6 to omega-3 PUFA ratio plays a key role in metabolic reactions in
muscle tissues.
In the present study, the placebo group also showed beneficial lipid effects such as the decrease of
palmitic acid and the significant increase of DGLA. It is well known that palmitic acid is positively
associated with inflammation, such as a decrease of interleukin-6. In this regard, a reduction of palmitic
acid may be a marker of inflammation reduction, even if, in our study, we did not show a correlation
between saturated FAs and CRP [60].
In relation to the increase of DGLA (20:3 omega-6), it is produced by the metabolism of gamma-LA
(18:3 omega-6) and can be incorporated into cellular glycerolipids (primarily phospholipids). Upon
cell activation, membrane-bound DGLA is released by the action of enzyme phospholipase A2(s) and
is converted into a mixture of metabolites with anti-inflammatory properties [61].
These lipidomic results sustain the hypothesis that a controlled diet with exercise may induce an
anti-inflammatory response. Supplementation has propitiously affected the pro-antioxidant status.
This is evident by the fact that GR levels increased significantly after supplementation whereas no
changes were found among the placebo-treated subjects. Few data are present in the literature
concerning whey protein supplementation and antioxidant metabolism, which are mainly related to
GSH synthesis [62].
The molecular mechanisms involved in the development of sarcopenia are still not fully understood.
However, there is a general consensus regarding the role of oxidative damage to muscle cells in
sarcopenia and muscle aging [6,63].
Several biochemical processes are involved in aging-associated muscular atrophy. Sarcopenia
mainly affects glycolytic fibers [64], which causes atrophy [65] via increased proteolytic activity [66,67].
It also makes them overproduce ROS [7,14,68]. Lastly, it destroys them through apoptosis or
programmed cell death [69,70]. All these processes could result from abnormal mitochondrial function,
since they are the main site of substrate oxidation, ROS production, and apoptosis.
These changes, which occur during aging, cannot be reversed but they may be reduced and
controlled. Dietary supplementation might be beneficial in countering the effects of aging and
age-related diseases. We speculate that the increase of the antioxidant enzyme GR, as observed in the
treated group, was due to the daily intake of vitamin D contained in the dietary supplement. A recent
study reported a novel link between vitamin D supplementation and improvement in cellular GSH.
Using a monocyte cell model, the study by Ruggiero et al. demonstrated that vitamin D up-regulates
the enzymes glutamate cysteine ligase (GCLC) and GR [71]. Then, some beneficial effects of vitamin
D supplementation may be mediated by an improvement in the cellular reduced GSH levels and a
decrease in ROS and pro-inflammatory cytokines.
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One of the limitations of our study is the lack of serum vitamin D assessment of the patients.
As such, we cannot consider whether there is a correlation between these parameters. Therefore, these
hypotheses will need to be investigated in future clinical trials.
Serum uric acid (UA) in humans is the end product of purine metabolism, and a number of studies
have shown that hyperuricemia is an important risk factor for systemic inflammation [72], endothelial
dysfunction [73], hypertension [74], impaired fasting glucose [75], cardiovascular disease (CVD), and
mortality [76]. Although a strong association exists among serum UA levels and various CVDs, a
normal level of UA has, so far, not been proven to have a pathogenic role but, instead, is considered to
be the ROS scavenger with strong antioxidant properties [77,78].
Thus, increased UA levels within the normal range may play an important protective role in
counteracting the excessive production of free radicals, especially in elderly patients. We performed an
exploratory analysis and found a correlation between UA and MDA (Figure 4) demonstrating that,
even in sarcopenic subjects, there is a relationship between oxidative stress and the UA level.
Various studies demonstrated that a higher circulating level of serum UA is prospectively
associated with higher handgrip strength in middle-aged and older individuals [79–81]. Our study
has not highlighted this correlation with muscle function.
5. Conclusions
In conclusion, this is the first study in the literature that describes the plasma lipid profile together
with pro-antioxidant status in a group of sarcopenic subjects before and after a randomized dietary
supplementation trial with personalized aerobic exercise and endurance training.
In both groups, we found, after 4 weeks of treatment, a change in the framework of FAs.
The evidence presented in this study suggests that dietary changes and physical activity are key factors
involved in the amelioration of the FA profile. The treated group, however, has the advantage of a
favorable increase in oleic acid associated with a decrease in LA and omega-6 PUFAs. In addition, only
the treated group showed improvement in antioxidant markers, which demonstrated an increase in
GR levels.
The study of the lipid profile in association with the study of the balance pro-antioxidant represents
a very interesting field of research in sarcopenic patients that has to be further explored and expanded
in detail.
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